Thompson RW, Liao S, Curci JA
Tablets: Pros: Non-invasive, easily incorporated into daily routines, and accessible without medical supervision
A larger vial and a larger reconstituted dose mean more systemic copper per administration if injected
Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray
55 The SURMOUNT Program includes four global phase 3, randomized, placebo-controlled clinical trials with tirzepatide administered subcutaneously once weekly in conjunction with lifestyle intervention.47, 48, 49 There was a substantial degree of weight reduction with 10 mg and 15 mg doses of 18.420.9% in persons with obesity or preobesity (without diabetes), with improvements in cardiometabolic risk factors (Table 2).47, 48, 49 Lower bodyweight reductions of 12.8% and 14.7% with 10 mg and 15 mg doses of tirzepatide, respectively, were observed in persons with preobesity or obesity and T2DM